Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeatMG: Rituximab in Myasthenia Gravis
NCT02110706Phase 2Completed
- Sponsor
- Yale University
- Start
- May 2014
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing Rituximab with Placebo (2 arms). Primary endpoints: Steroid Sparing Effect at 52 weeks and Percentage of Study Participants With Treatment-related Adverse Experiences at 52 weeks. Started May 2014; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02110706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110706.